The spectrum of neuromyelitis optica.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Lancet Neurology

• Publication date

  2007-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1474-4422(07)70216-8PMID 17706564
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Neuromyelitis optica and non organ-specific autoimmunity.

  2008cited by this paper
• NMO-IgG and Devic's neuromyelitis optica: a French experience

  2008cited by this paper
• NMO-IgG in the diagnosis of neuromyelitis optica

  2007cited by this paper
• Immunosuppressive therapy is more effective than interferon in neuromyelitis optica

  2007cited by this paper
• Neurology®

  2007cited by this paper
• Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis.

  2007cited by this paper
• Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica

  2007cited by this paper
• Multiple Sclerosis

  2007cited by this paper
• Revised diagnostic criteria for neuromyelitis optica (NMO)

  2007cited by this paper
• Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination.

  2007cited by this paper
• Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis.

  2007cited by this paper
• Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre.

  2007cited by this paper
• Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese.

  2007cited by this paper
• Absence of aquaporin-4 expression in lesions of neuromyelitis optica but increased expression in multiple sclerosis lesions and normal-appearing white matter

  2007cited by this paper
• A secondary progressive clinical course is uncommon in neuromyelitis optica

  2007cited by this paper
• Loss of aquaporin-4 in active perivascular lesions in neuromyelitis optica: a case report.

  2006cited by this paper
• The lumping and splitting of inflammatory CNS diseases

  2006cited by this paper
• [NMO-IgG antibodies in neuromyelitis optica: a report of 2 cases].

  2006cited by this paper
• Diffusion tensor imaging in the assessment of normal-appearing brain tissue damage in relapsing neuromyelitis optica.

  2006cited by this paper
• Multiple sclerosis--the plaque and its pathogenesis.

  2006cited by this paper
• Revised diagnostic criteria for neuromyelitis optica

  2006cited by this paper
• Progressive necrotizing myelopathy: part of the spectrum of neuromyelitis optica?

  2006cited by this paper
• Acute longitudinal myelitis as the initial manifestation of Sjögren’s syndrome

  2006cited by this paper
• Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG

  2006cited by this paper
• Neurological picture. Acute longitudinal myelitis as the initial manifestation of Sjögren's syndrome.

  2006cited by this paper
• Devic disease with brainstem lesions.

  2006cited by this paper
• Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression.

  2006cited by this paper
• Devic's syndrome in systemic lupus erythematosus and probable antiphospholipid syndrome.

  2006cited by this paper
• Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis

  2006cited by this paper
• OSMS is NMO, but not MS: proven clinically and pathologically.

  2006cited by this paper
• Recurrent optic neuromyelitis with endocrinopathies: a new syndrome or just a coincidence?

  2006cited by this paper
• Anticuerpos IgG-NMO en la neuromielitis óptica: a propósito de 2 casos

  2006cited by this paper
• Neuromyelitis optica diagnosis in clinically isolated syndromes suggestive of multiple sclerosis

  2006cited by this paper
• Brain abnormalities in neuromyelitis optica.

  2006cited by this paper
• Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease).

  2006cited by this paper
• An audit of the diagnostic usefulness of the NMO-IgG assay for neuromyelitis optica

  2006cited by this paper
• IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel

  2005cited by this paper
• Natural history of multiple sclerosis.

  2005cited by this paper
• Devic's disease and autoantibodies.

  2005cited by this paper
• Immunology of multiple sclerosis.

  2005cited by this paper
• Neuromyelitis optica

  2005cited by this paper
• Devic's syndrome in systemic lupus erythematosus and probable antiphospholipid syndrome.

  2005cited by this paper
• 0554 An autopsied case of Neuromyelitis Optica with a large cavitary cerebral lesion

  2005cited by this paper
• Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica

  2005cited by this paper
• An open label study of the effects of rituximab in neuromyelitis optica

  2005cited by this paper
• Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

  2005cited by this paper
• The Journal of Experimental Medicine CORRESPONDENCE

  2005cited by this paper
• Idiopathic severe recurrent transverse myelitis: a restricted variant of neuromyelitis optica.

  2005cited by this paper
• An autopsied case of neuromyelitis optica with a large cavitary cerebral lesion

  2005cited by this paper
• Neuromyelitis optica with hypothalamic involvement

  2005cited by this paper
• Acute transverse myelitis in SLE

  2004cited by this paper
• The natural history of recurrent optic neuritis.

  2004cited by this paper
• Spinal cord abnormalities in recently diagnosed MS patients

  2004cited by this paper
• Oligoclonal bands in Devic’s neuromyelitis optica and multiple sclerosis: differences in repeated cerebrospinal fluid examinations

  2004cited by this paper
• Recurrent transverse myelitis associates with anti-Ro (SSA) autoantibodies

  2004cited by this paper
• Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis

  2004cited by this paper
• Plasma exchange for severe optic neuritis

  2004cited by this paper
• Devic's Neuromyelitis Optica Treated with Intravenous Gamma Globulin (IVIG)

  2004cited by this paper
• Clinical characteristics, course and prognosis of relapsing Devic’s Neuromyelitis Optica

  2004cited by this paper
• Recurrent longitudinal myelitis as primary manifestation of SLE

  2004cited by this paper
• Recurrent transverse myelitis associates with anti-Ro (SSA) autoantibodies

  2004cited by this paper
• Mechanical ventilation and tracheostomy in multiple sclerosis

  2004cited by this paper
• A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.

  2004cited by this paper
• Magnetization transfer and diffusion tensor MRI show gray matter damage in neuromyelitis optica

  2004cited by this paper
• The molecular basis of water transport in the brain

  2003cited by this paper
• Is Devic's neuromyelitis optica a separate disease? A comparative study with multiple sclerosis

  2003cited by this paper
• Multiple sclerosis in the Japanese population.

  2003cited by this paper
• Neuromyelitis optica.

  2003cited by this paper
• Neuromyelitis optica: importance of cerebrospinal fluid examination during relapse

  2003cited by this paper
• Aquaporin water channels: molecular mechanisms for human diseases1

  2003cited by this paper
• Neuromyelitis optica

  2003cited by this paper
• Chronic relapsing inflammatory optic neuropathy (CRION).

  2003cited by this paper
• Neuromyelitis optica: what it is and what it might be.

  2003cited by this paper
• Epidemiological study of multiple sclerosis in Hong Kong Chinese: questionnaire survey.

  2002cited by this paper
• A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica.

  2002cited by this paper
• Plasma exchange for severe attacks of CNS demyelination: Predictors of response

  2002cited by this paper
• Optic neuromyelitis syndrome in Brazilian patients

  2002cited by this paper
• Devic's neuromyelitis optica: clinical, laboratory, MRI and outcome profile.

  2002cited by this paper
• Pure optic-spinal form of multiple sclerosis in Japan.

  2002cited by this paper
• Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group

  2002cited by this paper
• Neuromyelitis Optica

  2002cited by this paper
• Aboriginals with multiple sclerosis

  2001cited by this paper
• Diagnostic criteria for multiple sclerosis.

  2001cited by this paper
• Aboriginals with multiple sclerosis: HLA types and predominance of neuromyelitis optica.

  2001cited by this paper
• Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

  2001cited by this paper
• Demyelinating disorder of the central nervous system occurring in black South Africans

  2001cited by this paper
• MS and neuromyelitis optica in Martinique (French West Indies)

  2001cited by this paper
• Familial neuromyelitis optica (Devic’s syndrome) with late onset in Japan

  2000cited by this paper
• Multiple sclerosis.

  2000cited by this paper
• Hyperprolactinemia in optico-spinal multiple sclerosis.

  2000cited by this paper
• Both the HLA-CPB1 and -DRB1 alleles correlate with risk for multiple sclerosis in Japanese: clinical phenotypes and gender as important factors.

  2000cited by this paper
• Steroid-responsive Devic’s variant in Sjögren’s syndrome

  2000cited by this paper
• Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination

  2000cited by this paper
• Progressive necrotic myelopathy: clinical course in 9 patients.

  2000cited by this paper
• [HLA-DPB1* 0501-associated opticospinal multiple sclerosis: clinical, neuroimaging and immunogenetic studies].

  2000cited by this paper
• Clinical profile of multiple sclerosis in Bengal.

  1999cited by this paper
• The association of optic neuropathy with transverse myelitis in systemic lupus erythematosus.

  1999cited by this paper
• The clinical course of neuromyelitis optica (Devic’s syndrome)

  1999cited by this paper
• A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease

  1999cited by this paper
• MRI and magnetization transfer imaging changes in the brain and cervical cord of patients with Devic’s neuromyelitis optica

  1999cited by this paper

• The evolution and current status of anti-B-cell therapies in autoimmune neurologic diseases.

  2026cites this paper
• Immunotherapies for neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease.

  2026cites this paper
• Therapeutic immune tolerance for central nervous system autoimmune diseases - Prospects, challenges and pitfalls.

  2026cites this paper
• Neurological and paraclinical features differentiating Systemic lupus erythematosus, Sjögren's disease, and neuromyelitis optica spectrum disorders.

  2026cites this paper
• A Clinical Profile of Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders in a Tertiary Care Hospital in South Tamil Nadu

  2026cites this paper
• Dysregulated Tfh/B cells and their interactions in neuromyelitis optica spectrum disorder

  2026cites this paper
• From the Optic Neuritis Treatment Trial to Antibody-Mediated Optic Neuritis: Four Decades of Progress and Unanswered Questions.

  2026cites this paper
• Exploration of the source of AQP4 antibody: Based on paired serum and cerebrospinal fluid samples from 98 patients.

  2026cites this paper
• Myelitis-Predominant Aggressive Phenotype: Unveiling Unique Patterns of Late-Onset Neuromyelitis Optica Spectrum Disorders.

  2026cites this paper
• Pediatric neuromyelitis optica spectrum disorders in Dakar: Insights from a preliminary multicentric case series in Senegal.

  2026cites this paper
• Polymorphonuclear myeloid-derived suppressor cells inhibit natural killer cell function in neuromyelitis optica spectrum disorder via the CD155-TIGIT axis.

  2026cites this paper
• Eculizumab as a rescue therapy in acute-phase aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder

  2026cites this paper
• AQP4-IgG-Negative Neuromyelitis Optica Spectrum Disorder Complicated with Sjögren’s Syndrome Presenting with Area Postrema Syndrome: A Case Report

  2026cites this paper
• Relapse-related outcomes in the Danish population-based AQP4- antibody seropositive neuromyelitis optica spectrum disorder cohort

  2026cites this paper
• Ravulizumab in NMOSD with associated interstitial pneumonitis in a 59-year-old female patient: a case report

  2026cites this paper
• Somatosensory evoked potentials in neuromyelitis optica spectrum disorders.

  2026cites this paper
• Neutrophil-microglia interaction drives motor dysfunction in neuromyelitis optica model induced by subarachnoid AQP4-IgG.

  2026cites this paper
• A Case of Neuromyelitis Optica Spectrum Disorder Complicated by Posterior Reversible Encephalopathy Syndrome With Pre-existing Sjögren's Syndrome and Autoimmune Hepatitis

  2025cites this paper
• Concomitant Sjögren’s disease in patients with NMOSD: impacts on neurologic disease severity and recurrence

  2025cites this paper
• Recommendations on NMOSD treatment in Latin America: Utilizing consensus-based RAND/UCLA methodology.

  2025cites this paper
• Reporting Two Cases of Spinal ADEM and Short Review of Clinical and Radiological Evaluation of Acute Demyelination of Spinal Cord

  2025cites this paper
• Comparison of Clinical and Imaging Parameters in Patients With Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Prospective Observational Study

  2025cites this paper
• Pediatric-Onset Neuromyelitis Optica Spectrum Disorder in Isfahan: Insights from a Cross-Sectional Study

  2025cites this paper
• Acute symptomatic seizures and epilepsy in pediatric patients with central nervous system inflammatory demyelinating diseases.

  2025cites this paper
• CFHR2 Supplementation Mitigates Pathologies of Neuromyelitis Optica by Regulating Complement Activation.

  2025cites this paper
• High‐Efficacy Treatment in Neuromyelitis Optica Specturm Disorder Patients With Seropositive AQP4 Antibodies—A Real‐World Study

  2025cites this paper
• Early neuromyelitis optica antibody-induced molecular changes in aquaporin 4 and associated proteins at astrocyte endfeet in murine brain tissues.

  2025cites this paper
• Immune-related biomarkers in the neuromyelitis optica spectrum disorder; pathogenesis and therapeutic approaches.

  2025cites this paper
• Comparison of the clinical and laboratory characteristics of neuromyelitis optica spectrum disorder with or without cerebrospinal fluid oligoclonal bands: a cohort with 36-month follow-up

  2025cites this paper
• Efficacy of human umbilical cord mesenchymal stem cell in the treatment of neuromyelitis optica spectrum disorders: an animal study

  2025cites this paper
• Eculizumab for the acute attack of neuromyelitis optica spectrum disorder

  2025cites this paper
• An Exploratory Study on a Potential Biomarker for Seizures in Autoimmune Encephalitis

  2025cites this paper
• The association of HLA-DQB1*04 and DQB1*03 with neuromyelitis optica spectrum disorders: A case–control study considering genetic ancestry

  2025cites this paper
• A Chinese girl with neuromyelitis optica spectrum disorder coexisting with primary Sjogren’s syndrome: a case report and literature review

  2025cites this paper
• Associations between serum levels of alpha-calcitonin gene-related peptide and clinical features of neuromyelitis optica spectrum disorders.

  2025cites this paper
• Advancing Optical Coherence Tomography Diagnostic Capabilities: Machine Learning Approaches to Detect Autoimmune Inflammatory Diseases.

  2025cites this paper
• Advances in maintenance therapies for neuromyelitis optica spectrum disorders: A new era of targeted drugs.

  2025cites this paper
• Analysis of infection rates in neuromyelitis optica spectrum disorder: Comparing satralizumab treatment in SAkuraMoon, post-marketing, and US-based health claims data.

  2025cites this paper
• Influencing factors and clinical value of anti-aquaporin-4 antibody in cerebrospinal fluid: a study of 82 patients with neuromyelitis optica spectrum disorder

  2025cites this paper
• Clinical characteristics of late-onset neuromyelitis optica spectrum disorder in China.

  2025cites this paper
• Study of sleep abnormalities in patients with NMOSD-MOG related disorders.

  2025cites this paper
• Preference for Inebilizumab Home Infusion Among People with Neuromyelitis Optica Spectrum Disorder (P12-8.003)

  2025cites this paper
• Multimodal AI diagnostic system for neuromyelitis optica based on ultrawide-field fundus photography

  2025cites this paper
• Detrimental Roles of Innate Immune cells in Neuromyelitis Optica Spectrum Disorder: Pathogenesis and Therapeutic Targeting.

  2025cites this paper
• Pathogenic role of CD169+ macrophages in neuronal loss and motor decline in NMO mice.

  2025cites this paper
• FCRL3 genetic variants drive autoimmune pathogenesis in multiple sclerosis and neuromyelitis optica spectrum disorders

  2025cites this paper
• Anti-SRP antibody-positive polymyositis complicated by neuromyelitis optica spectrum disorder: A case report and literature review.

  2025cites this paper
• Diagnostic pitfalls in multiple sclerosis: how to avoid mistakes

  2025cites this paper
• Point-of-care testing of neuromyelitis optica spectrum disorder using a sonochemically enhanced bifunctional CdTe-ZIF-8 nanohybrids-labelled lateral flow immunoassay

  2025cites this paper
• Severe neurological manifestations of LETM with brainstem involvement: A dual case report

  2025cites this paper
• Antibody glycosylation in neuroimmune diseases

  2025cites this paper
• Adherence to the MIND diet and onset of neuromyelitis optica spectrum disorder: A case-control study.

  2025cites this paper
• Therapeutic effect of topiramate on paroxysmal tonic spasms in a Chinese woman with neuromyelitis optica spectrum disease: A case report.

  2025cites this paper
• Microglial estrogen receptor 1 signal designates sexual dimorphism of AQP4 antibody-induced neuroinflammation and demyelination.

  2025cites this paper
• Telitacicept Inhibits the Maturation and Differentiation of B Lymphocytes in NMOSD

  2025cites this paper
• Emerging Role of Targeted Monoclonal Antibodies in Neuromyelitis Optica Spectrum Disorders

  2025cites this paper
• Modulation of antibody transport in the brain and spinal cord through the intranasal pathway

  2025cites this paper
• Immunotherapy for neuromyelitis optica spectrum disorder: a comparative analysis of efficacy and safety of azathioprine, mycophenolate mofetil, tacrolimus, and rituximab

  2025cites this paper
• Nationwide epidemiological study of neuromyelitis optica spectrum disorder in Serbia.

  2025cites this paper
• Seropositive longitudinally extensive transverse myelitis following unilateral pneumonia

  2025cites this paper
• The Percentage of Neutrophils is Independently Associated with Blood-Brain Barrier(BBB) Disruption in Myelin Oligodendrocyte Glycoprotein Antibody Associated Disease (MOGAD)

  2025cites this paper
• A Case Report of Neuromyelitis Optica Spectrum Disorder (NMOSD) Treatment in Resource‐Limited Setup: An Ethiopian Experience

  2025cites this paper
• Factors associated with cognitive impairment in patients with neuromyelitis optica spectrum disorders from Mexico

  2025cites this paper
• ECTRIMS 2024 Lecture: Unraveling the spectrum of the antibody-mediated demyelinating diseases: Emerging insights

  2025cites this paper
• Neuromyelitis Optica Mimicking Multiple Sclerosis: A Case Report and a Comprehensive Review of the Literature

  2025cites this paper
• Induction of immune tolerance in NMOSD and MOGAD

  2025cites this paper
• Switching from Rituximab to Eculizumab in US Patients with Neuromyelitis Optica Spectrum Disorder: Impact on Hospitalizations

  2025cites this paper
• Diagnosis of longitudinally extensive transverse myelitis

  2025cites this paper
• Spectre des maladies inflammatoires primitives du système nerveux : expérience du suivi de patients dans un pays subsaharien. Cas de la Côte d’Ivoire (Abidjan)

  2025cites this paper
• Cellular therapy in neuromyelitis optica spectrum disorder

  2025cites this paper
• Clinical characteristics of anti-myelin oligodendrocyte glycoprotein antibody among aquaporin-4 negative neuromyelitis optica spectrum disorders in Egyptian patients

  2025influential citation
• Neuromyelitis Optica-Associated Acute Intermediate Uveitis

  2025cites this paper
• Urinary Tract Infection Masquerading as a Neuromyelitis Optica Spectrum Disorder Exacerbation: A Case Report

  2025cites this paper
• Cerebellar microstructural and functional connectivity changes in patients with neuromyelitis optica spectrum disorders and their correlation with cognitive function: a female-dominated multimodal MRI study

  2025cites this paper
• Neutrophil-microglia interaction drives reversible motor dysfunction in neuromyelitis optica model induced by subarachnoid AQP4-IgG

  2025cites this paper
• Atypical Neuromyelitis Optica Spectrum Disorder: A Case of Unilateral Optic Neuritis and Partial Transverse Myelitis

  2025cites this paper
• Correlation between fatigue and quality of life among patients with neuromyelitis optica in West China

  2025cites this paper
• Sex ratio and age of onset in AQP4 antibody-associated NMOSD: a review and meta-analysis

  2024cites this paper
• A case of tubercular meningoencephalitis with transverse myelitis

  2024cites this paper
• GV‐971 attenuates the progression of neuromyelitis optica in murine models and reverses alterations in gut microbiota and associated peripheral abnormalities

  2024cites this paper
• Rituximab Therapy for Double Seronegative Neuromyelitis Optica Spectrum Disease

  2024cites this paper
• Efficacy and safety of apheresis therapy in AQP4 antibody‐positive NMOSD attack: A propensity score‐matched cohort study

  2024cites this paper
• Protein-A immunoadsorption combined with immunosuppressive treatment in refractory primary Sjögren’s syndrome coexisting with NMOSD: a case report and literature review

  2024cites this paper
• Exploration of the causal associations between circulating inflammatory proteins, immune cells, and neuromyelitis optica spectrum disorder: a bidirectional Mendelian randomization study and mediation analysis

  2024cites this paper
• Biomarkers for neuromyelitis optica: a visual analysis of emerging research trends

  2024cites this paper
• Devic’s disease: Neuromyelitis optica spectrum disorder – A case series

  2024cites this paper
• Interest of rare autoantibodies in autoimmune encephalitis and paraneoplastic neurological syndromes: the utility (or futility) of rare antibody discovery

  2024cites this paper
• Differentiated pattern of complement system activation between MOG-IgG-associated disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder

  2024cites this paper
• Monoclonal antibodies in neuro-ophthalmology

  2024cites this paper
• Perspectivas para o tratamento da neuromielite óptica: uma revisão de literatura

  2024cites this paper
• Démarche diagnostique devant des hypersignaux de la substance blanche cérébrale

  2024cites this paper
• Review of Satralizumab for Neuromyelitis Optica Spectrum Disorder: A New Biologic Agent Targeting the Interleukin-6 Receptor

  2024cites this paper
• Interferon Regulatory Factor 5 Gene Polymorphisms and mRNA Expression Levels Are Associated with Neuromyelitis Optica Spectrum Disorder

  2024cites this paper
• 'I Thought It Was My Diabetes': An Acute Presentation of Neuromyelitis Optica Spectrum Disorder.

  2024cites this paper
• Emerging functions and therapeutic targets of IL‐38 in central nervous system diseases

  2024cites this paper
• Interactions Between Extracellular Vesicles and Autophagy in Neuroimmune Disorders

  2024cites this paper
• A Comparative Review of Typical and Atypical Optic Neuritis: Advancements in Treatments, Diagnostics, and Prognosis

  2024cites this paper
• Immediate and sustained terminal complement inhibition with ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder

  2024cites this paper
• Altered immune co-inhibitory receptor expression and correlation of LAG-3 expression to disease severity in NMOSD.

  2024cites this paper
• Prevalence of neuromyelitis optica spectrum disorder in the United States

  2024cites this paper